JAAOS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

J Am Acad Orthop Surg, Vol 10, No 6, November/December 2002, 393-400.
© 2002 the American Academy of Orthopaedic Surgeons
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Keating, E. M.
Right arrow Articles by Meding, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keating, E. M.
Right arrow Articles by Meding, J. B.

Perioperative Blood Management Practices in Elective Orthopaedic Surgery

E. Michael Keating, MD and John B. Meding, MD

Dr. Keating is Orthopaedic Surgeon, The Center for Hip and Knee Surgery, Mooresville, IN. Dr. Meding is Orthopaedic Surgeon, The Center for Hip and Knee Surgery, Mooresville.

Reprint requests: Dr. Keating, 1199 Hadley Road, Mooresville, IN 46158.

Concern about the cost and safety of allogenic blood transfusion, including the risk of viral infection and immunosuppression, has led to refinements in and new approaches to blood conservation, including the development of transfusion practice standards and improvements in surgical practice. Preoperative autologous blood collection, the use of hemostatic agents, perioperative blood salvage, and the use of recombinant human erythropoietin (epoetin alfa) to stimulate erythropoiesis have contributed to decreased use of allogenic blood services. Development of appropriate blood management strategies to help reduce or eliminate exposure to allogenic blood requires a preoperative assessment of the likelihood of transfusion and of the risks as well as costs associated with conservation and replacement options. The informed selection of alternatives based on preoperative assessment of hematologic status, estimated blood loss, and sources for blood replacement may enhance blood management practices in major elective orthopaedic surgery.




This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
D. Jaspan
Erythropoietic therapy: Cost efficiency and reimbursement
Am. J. Health Syst. Pharm., August 15, 2007; 64(16_Supplement_11): S19 - S29.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Academy of Orthopaedic Surgeons.